Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Shares Bought by GAMMA Investing LLC

GAMMA Investing LLC grew its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 4,003.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 27,496 shares of the company’s stock after acquiring an additional 26,826 shares during the quarter. GAMMA Investing LLC’s holdings in Kiniksa Pharmaceuticals International were worth $611,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Lazard Asset Management LLC acquired a new stake in Kiniksa Pharmaceuticals International in the 4th quarter valued at about $61,000. KLP Kapitalforvaltning AS acquired a new stake in Kiniksa Pharmaceuticals International in the 4th quarter valued at about $158,000. Bellevue Group AG acquired a new stake in Kiniksa Pharmaceuticals International in the 4th quarter valued at about $160,000. Tower Research Capital LLC TRC lifted its holdings in Kiniksa Pharmaceuticals International by 117.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company’s stock valued at $168,000 after acquiring an additional 4,575 shares during the last quarter. Finally, Teacher Retirement System of Texas lifted its holdings in Kiniksa Pharmaceuticals International by 7.1% in the 4th quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company’s stock valued at $215,000 after acquiring an additional 719 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Insider Buying and Selling

In related news, insider Ross Moat sold 18,259 shares of the stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $20.29, for a total value of $370,475.11. Following the transaction, the insider now owns 9,415 shares in the company, valued at approximately $191,030.35. This represents a 65.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Eben Tessari sold 45,042 shares of the stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $30.51, for a total value of $1,374,231.42. Following the completion of the transaction, the chief operating officer now owns 72,363 shares in the company, valued at $2,207,795.13. This represents a 38.36% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 440,863 shares of company stock worth $12,101,029. Insiders own 53.48% of the company’s stock.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA opened at $27.93 on Thursday. The company has a market capitalization of $2.04 billion, a price-to-earnings ratio of -111.72 and a beta of 0.06. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $17.38 and a fifty-two week high of $30.69. The business’s 50-day moving average is $25.63 and its 200-day moving average is $22.29.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals International had a negative return on equity of 3.83% and a negative net margin of 3.52%. The firm had revenue of $137.79 million for the quarter, compared to the consensus estimate of $128.35 million. During the same quarter in the prior year, the company posted ($0.25) earnings per share. The firm’s revenue was up 72.5% on a year-over-year basis. Equities research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on KNSA shares. Jefferies Financial Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Tuesday, April 29th. Citigroup started coverage on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, March 13th. They set a “buy” rating and a $40.00 price objective for the company. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “buy” rating in a report on Saturday, June 14th. Finally, Wedbush reiterated an “outperform” rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, April 16th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $38.80.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.